DermaLumics‘ success has only been possible due the credibility and the sustainability that was given to his project by their investors



Ysios Capital is a leading Spanish independent venture capital firm that provides private equity financing to early- and mid-stage human healthcare and life science companies. They target the entire healthcare and biotechnology industry, with a special focus on pharmaceuticals, diagnostics and medical devices.

Founded in 2008, Ysios Capital currently has close to €200M ($220M) in assets under management. Ysios BioFund II Innvierte was closed in September 2016 at €126.4M

Their team includes experienced professionals with extensive complementary expertise in investing and building healthcare and biotechnology companies. Ysios Capital has access to a broad global network within academia, finance and industry. They take an active role in the development of their portfolio companies as a lead investor or as an active syndicate partner.

Ysios Capital is registered at the Spanish Securities and Exchange Commission (CNMV). Its main office is in Barcelona.

The current portfolio de Ysios Capital is:

  • AM-Pharma (Netherlands);
  • CVRx (USA);
  • Inbiomotion (Spain);
  • Kala Pharmaceuticals (USA);
  • MedLumics (Spain);
  • STAT-Diagnostica (Spain);
  • TiGenix (Belgium).